Benzinga··Vandana SinghNovo Nordisk's CagriSema Falls Short in Weight-Loss Trial Against Lilly's Tirzepatide
Novo Nordisk's CagriSema underperformed Eli Lilly's tirzepatide in weight-loss trials, delivering 20.2% versus 23.6% weight reduction, triggering stock declines amid intensifying obesity drug competition.
LLYNVOclinical trialtirzepatide